Serum protein profile in systemic-onset juvenile idiopathic arthritis differentiates response versus nonresponse to therapy.
Serum protein profile in systemic-onset juvenile idiopathic arthritis differentiates response versus nonresponse to therapy.
复制标题
全身性特发性关节炎中的血清蛋白质谱分化与对治疗无反应的反应。
DOI：
10.1186/ar1723
复制
发表时间：
2005
影响因子：
4.9
通讯作者：
Hirsch R
中科院分区：
文献类型：
--
作者：
Miyamae T;Malehorn DE;Lemster B;Mori M;Imagawa T;Yokota S;Bigbee WL;Welsh M;Klarskov K;Nishomoto N;Vallejo AN;Hirsch R
全身性幼年特发性关节炎（SJIA）是一种病因不明的疾病，治疗反应不可预测。我们检查了两组患者，以确定是否存在反映活动性疾病并预测治疗反应的血清蛋白谱。第一组（n = 8）对常规疗法有反应。第二组 (n = 15) 对 IL-6 受体 (MRA) 实验抗体有反应。使用表面增强激光解吸/电离飞行时间质谱 (SELDI-TOF MS) 分析每位患者治疗前后的配对血清。尽管患者数量较少，但所有患者在治疗反应前后均观察到高度显着且一致的差异。在识别的 282 个光谱峰中，23 个的平均信号强度在治疗前和治疗后有显着差异 (P < 0.001)。无论患者是否对常规治疗或 MRA 有反应，这些差异中的大部分都是观察到的。这些峰代表活动性疾病的潜在生物标志物。其中一个峰被鉴定为血清淀粉样蛋白 A，这是 SJIA 中一种已知的急性期反应物，验证了 SELDI-TOF MS 平台在这种情况下是一种有用的技术。最后，对两个患者组之间在疾病活动时获得的血清样本的概况进行比较。对常规治疗有反应的患者和无反应的患者的活动性疾病之间，九个峰值的平均信号强度显着不同（P < 0.001），这表明可能存在预测反应的情况。总的来说，这些数据证明了 SJIA 中存在反映活动性疾病的血清蛋白质组谱，并表明使用 SELDI-TOF MS 平台作为蛋白质组谱分析和发现自身免疫性疾病新型生物标志物的工具的可行性。
Systemic-onset juvenile idiopathic arthritis (SJIA) is a disease of unknown etiology with an unpredictable response to treatment. We examined two groups of patients to determine whether there are serum protein profiles reflective of active disease and predictive of response to therapy. The first group (n = 8) responded to conventional therapy. The second group (n = 15) responded to an experimental antibody to the IL-6 receptor (MRA). Paired sera from each patient were analyzed before and after treatment, using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS). Despite the small number of patients, highly significant and consistent differences were observed before and after response to therapy in all patients. Of 282 spectral peaks identified, 23 had mean signal intensities significantly different (P < 0.001) before treatment and after response to treatment. The majority of these differences were observed regardless of whether patients responded to conventional therapy or to MRA. These peaks represent potential biomarkers of active disease. One such peak was identified as serum amyloid A, a known acute-phase reactant in SJIA, validating the SELDI-TOF MS platform as a useful technology in this context. Finally, profiles from serum samples obtained at the time of active disease were compared between the two patient groups. Nine peaks had mean signal intensities significantly different (P < 0.001) between active disease in patients who responded to conventional therapy and in patients who failed to respond, suggesting a possible profile predictive of response. Collectively, these data demonstrate the presence of serum proteomic profiles in SJIA that are reflective of active disease and suggest the feasibility of using the SELDI-TOF MS platform used as a tool for proteomic profiling and discovery of novel biomarkers in autoimmune diseases.
登录
查看更多内容
影响因子：
168.9
作者：
Petricoin, EF;Ardekani, AM;Liotta, LA
通讯作者：
Liotta, LA
影响因子：
5
作者：
Tolson, J;Bogumil, R;Flad, T
通讯作者：
Flad, T
影响因子：
5.1
作者：
Wright, George L Jr
通讯作者：
Wright, George L Jr
影响因子：
--
作者：
DEBENEDETTI, F;MASSA, M;MARTINI, A
通讯作者：
MARTINI, A
影响因子：
27.4
作者：
SCHEINBERG, MA;HUBSCHER, O;BENSON, MD
通讯作者：
BENSON, MD